CFTR and cystic fibrosis: This notion is supported by our nasal potential difference measurements demonstrating that ETI therapy improves constitutive and cAMP-induced CFTR activity in the nasal epithelium of CF patients with at least 1 F508del allele in vivo (Figure 5).